Drugs / ALD-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00654433 | Mar 2008 → Jul 2011 | mucopolysaccharidosis, peroxisomal disease | Aldagen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00654433 ↗ |
| Modality | Cell therapy | “20% supplemental stem cell called ALD-101” NCT00654433 ↗ |